These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 7790956

  • 41. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457.
    Talvik M, Nordström AL, Nyberg S, Olsson H, Halldin C, Farde L.
    Am J Psychiatry; 2001 Jun; 158(6):926-30. PubMed ID: 11384901
    [Abstract] [Full Text] [Related]

  • 42. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, Mazière B, Paillère-Martinot ML.
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [Abstract] [Full Text] [Related]

  • 43. High-affinity dopamine D2/D3 PET radioligands 18F-fallypride and 11C-FLB457: a comparison of kinetics in extrastriatal regions using a multiple-injection protocol.
    Vandehey NT, Moirano JM, Converse AK, Holden JE, Mukherjee J, Murali D, Nickles RJ, Davidson RJ, Schneider ML, Christian BT.
    J Cereb Blood Flow Metab; 2010 May; 30(5):994-1007. PubMed ID: 20040928
    [Abstract] [Full Text] [Related]

  • 44. Reproducibility of post-amphetamine [11C]FLB 457 binding to cortical D2/3 receptors.
    Narendran R, Himes M, Mason NS.
    PLoS One; 2013 May; 8(9):e76905. PubMed ID: 24098812
    [Abstract] [Full Text] [Related]

  • 45. Fluorine-18-labelled NCQ 115, a selective dopamine D-2 receptor ligand. Preparation and positron emission tomography.
    Halldin C, Högberg T, Farde L.
    Nucl Med Biol; 1994 May; 21(4):627-31. PubMed ID: 9234320
    [Abstract] [Full Text] [Related]

  • 46. No regional difference in dopamine D2 receptor occupancy by the second-generation antipsychotic drug risperidone in humans: a positron emission tomography study.
    Ito H, Arakawa R, Takahashi H, Takano H, Okumura M, Otsuka T, Ikoma Y, Shidahara M, Suhara T.
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):667-75. PubMed ID: 18937879
    [Abstract] [Full Text] [Related]

  • 47. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.
    Cervenka S, Pålhagen SE, Comley RA, Panagiotidis G, Cselényi Z, Matthews JC, Lai RY, Halldin C, Farde L.
    Brain; 2006 Aug; 129(Pt 8):2017-28. PubMed ID: 16816393
    [Abstract] [Full Text] [Related]

  • 48. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics.
    Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, Sudo Y, Inoue M, Okubo Y.
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):19-26. PubMed ID: 14764214
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. PET studies of D2-receptor binding in striatal and extrastriatal brain regions: Biochemical support in vivo for separate dopaminergic systems in humans.
    Cervenka S, Varrone A, Fransén E, Halldin C, Farde L.
    Synapse; 2010 Jun; 64(6):478-85. PubMed ID: 20175222
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Mapping of central D2 dopamine receptors in man using [11C]raclopride: PET with anatomic standardization technique.
    Ito H, Okubo Y, Halldin C, Farde L.
    Neuroimage; 1999 Feb; 9(2):235-42. PubMed ID: 9927552
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study.
    Kaasinen V, Aalto S, NAgren K, Hietala J, Sonninen P, Rinne JO.
    J Neural Transm (Vienna); 2003 Jun; 110(6):591-601. PubMed ID: 12768355
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.
    Narendran R, Mason NS, Chen CM, Himes M, Keating P, May MA, Rabiner EA, Laruelle M, Mathis CA, Frankle WG.
    Synapse; 2011 Oct; 65(10):991-7. PubMed ID: 21360596
    [Abstract] [Full Text] [Related]

  • 60. Carbon-11 pb-12: an attempt to visualize the dopamine d(4) receptor in the primate brain with positron emission tomography.
    Langer O, Halldin C, Chou Y, Sandell J, Swahn C, Någren K, Perrone R, Berardi F, Leopoldo M, Farde L.
    Nucl Med Biol; 2000 Nov; 27(8):707-14. PubMed ID: 11150701
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.